Addition of IMP3 to L1CAM for discrimination between low- and high-grade endometrial carcinomas: an ENITEC collaboration study

Nicole C.M. Visser MD\textsuperscript{1,2}, Louis J.M. van der Putten MD, PhD\textsuperscript{3}, Alex van Egerschot BSc\textsuperscript{1}, Koen K. Van de Vijver MD, PhD\textsuperscript{4}, Maria Santacana, PhD\textsuperscript{5}, Peter Bronsert MD, PhD\textsuperscript{6,7,8}, Marc Hirschfeld MD, PhD\textsuperscript{9,10}, Eva Colas PhD\textsuperscript{11}, Antonio Gil-Moreno MD, PhD\textsuperscript{11,12}, Angel Garcia MD, PhD\textsuperscript{13}, Gemma Mancebo MD, PhD\textsuperscript{14}, Francesc Alameda MD, PhD\textsuperscript{15}, Camilla Krakstad MS, PhD\textsuperscript{16,17}, Ingvild L. Tangen PhD\textsuperscript{16,17}, Jutta Huvila MD, PhD\textsuperscript{18}, Stefanie Schrauwen, PhD\textsuperscript{19}, Martin Koskas MD, PhD\textsuperscript{20}, Francine Walker MD, PhD\textsuperscript{21}, Vit Weinberger MD, PhD\textsuperscript{22}, Lubos Minar MD, PhD\textsuperscript{22}, Jitka Hausnerova MD\textsuperscript{23}, Marc P.L.M. Snijders MD, PhD\textsuperscript{24}, Saskia van den Berg-van Erp MD, PhD\textsuperscript{25}, Xavier Matias-Guiu MD, PhD\textsuperscript{2}, Jone Trovik MD, PhD\textsuperscript{16,17}, Frédéric Amant MD, PhD\textsuperscript{19,26}, Leon F.A.G. Massuger MD, PhD\textsuperscript{3}, Johan Bulten MD, PhD\textsuperscript{1}, Johanna M.A. Pijnenborg MD, PhD\textsuperscript{3}

\textsuperscript{1}Department of Pathology, Radboud university medical centre, 6500HB, Nijmegen, the Netherlands
\textsuperscript{2}Radboud Institute for Molecular Life Sciences, 6500HB, Nijmegen, the Netherlands
\textsuperscript{3}Department of Obstetrics and Gynaecology, Radboud university medical centre, 6500HB, Nijmegen, the Netherlands
\textsuperscript{4}Department of Pathology, Ghent University Hospital, 9000, Ghent, Belgium
\textsuperscript{5}Department of Pathology and Molecular Genetics and Oncological Pathology Group, Hospital Universitari Arnau de Vilanova, University of Lleida, IRBLLEIDA, CIBERONC, 25198, Lleida, Spain
\textsuperscript{6}Institute for Surgical Pathology, Medical Centre – University of Freiburg, 79085, Freiburg, Germany
\textsuperscript{7}Comprehensive Cancer Centre Freiburg, Medical Centre – University of Freiburg, 79106, Freiburg, Germany
\textsuperscript{8}Faculty of Medicine, University of Freiburg, 79085, Freiburg, Germany
\textsuperscript{9}Department of Obstetrics and Gynaecology, University Medical Centre Freiburg, 79106, Freiburg, Germany
German Cancer Consortium (DKTK), German Cancer Research Centre (DKFZ), 69120, Heidelberg, Germany

Biomedical Research Group in Gynaecology, Vall Hebron Institute of Research (VHIR), Universitat Autònoma de Barcelona, CIBERONC, 08193, Barcelona, Spain

Gynecological Department, Vall Hebron University Hospital, CIBERONC, 8035, Barcelona, Spain

Pathology Department, Vall Hebron University Hospital, 8035, Barcelona, Spain

Department of Obstetrics and Gynaecology, Hospital del Mar, 8003, Barcelona, Spain

Department of Pathology, Hospital del Mar, 8003, Barcelona, Spain

Department of Obstetrics and Gynaecology, Haukeland University Hospital, 5021, Bergen, Norway

Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, 5021, Bergen, Norway

Department of Pathology, University of Turku, 20500, Turku, Finland

Division of Gynaecologic Oncology, Department of Obstetrics and Gynaecology, University Hospital Gasthuisberg, 3000, Leuven, Belgium

Obstetrics and Gynaecology Department, Bichat-Claude Bernard Hospital, 75877, Paris, France

Pathology Department, Bichat-Claude Bernard Hospital, 75877, Paris, France

Department of Obstetrics and Gynaecology, University Hospital Brno, Faculty of Medicine, Masaryk University, 62500 Brno, Czech Republic

Department of Pathology, University Hospital Brno, Faculty of Medicine, Masaryk University, 62500 Brno, Czech Republic

Department of Obstetrics and Gynaecology, Canisius-Wilhelmina Hospital, 6500 GS, Nijmegen, the Netherlands

Department of Pathology, Canisius-Wilhelmina Hospital, 6500 GS, Nijmegen, the Netherlands

Department of Gynaecologic Oncology, Centre Gynaecologic Oncology Amsterdam (CGOA), Netherlands Cancer Institute and Amsterdam University Medical Centres, Academic Medical Centre, 1105 AZ, Amsterdam, the Netherlands

Short title: IMP3 in endometrial carcinomas

Conflict of interest: The authors declare no conflict of interest.
Funding source: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

_Corresponding author_

Nicole C.M. Visser

Department of Pathology
Radboud university medical center
P.O. Box 9101, 6500 HB Nijmegen; the Netherlands
E-mail: Nicole.Visser@radboudumc.nl
Telephone: +31243614314 (voice)
+31243619637 (fax)
Abstract

Discrimination between low- and high-grade endometrial carcinomas (ECs) is clinically relevant, but can be challenging for pathologists with moderate interobserver agreement.

Insulin-like growth factor-II mRNA-binding protein 3 (IMP3) is an oncofoetal protein that is associated with non-endometrioid endometrial carcinomas, but has been limited studied in endometrioid carcinomas. The aim of this study is to investigate the diagnostic and prognostic value of IMP3 in the discrimination between low- and high-grade ECs, and its added value to L1CAM.

IMP3 and L1CAM expression was assessed in tumours from 378 patients treated for EC at one of nine participating ENITEC centres. IMP3 was expressed in 24.6% of the tumours. In general, IMP3 was more homogeneously expressed than L1CAM. IMP3 expression was significantly associated with advanced stage, non-endometrioid histology, grade 3 tumours, deep myometrial invasion, lymphovascular space invasion (LVSI), distant recurrences, overall mortality, and disease-related mortality. Simultaneous absence of IMP3 and L1CAM expression showed the highest accuracy for identifying low-grade carcinomas (AUC 0.766), whereas simultaneous expression of IMP3 and L1CAM was strongly associated with high-grade carcinomas (OR 19.7; 95% CI 9.2-42.2). Even within endometrioid carcinomas, this combination remained superior to IMP3 and L1CAM alone (OR 8.6; 95% CI 3.4-21.9).

In conclusion, IMP3 has good diagnostic value and together with L1CAM represents the optimal combination of diagnostic markers for discrimination between low- and high-grade ECs compared to IMP3 and L1CAM alone. Because of the homogenous expression of IMP3, this marker might be valuable in preoperative biopsies when compared to the more patchy L1CAM expression.
Keywords: endometrial carcinoma, diagnostic biomarker, prognostic biomarker, IMP3, L1CAM
1. Introduction

Endometrial carcinoma (EC) is the most common gynaecological cancer in developed countries and the fourth most common after breast, lung, and colorectal cancer [1]. Patients with localized disease (International Federation of Gynaecology and Obstetrics [FIGO] 2009 stage I and II) have a good prognosis, with a five-year survival of 95% [1]. However, when there is regional disease spread, the five-year survival rate is 69%, and in the presence of distant metastases only 17% [1]. Contrary to the decreasing death rates for most cancers, mortality for EC has increased since 2000 [1].

According to the WHO Classification ECs are divided into endometrioid (EEC) and non-endometrioid carcinomas (NEECs), including serous, clear cell carcinomas, carcinosarcomas and undifferentiated carcinomas [2]. EECs comprise 80%, and NEECs 20% of all carcinomas. NEECs are high-grade, have a more aggressive course, and subsequently a worse prognosis [3]. EECs are graded from grade 1 to 3, primarily based on their percentage of solid growth [2]. All NEECs are considered to be grade 3 carcinomas [2]. Grade 3 EECs and NEECs are classically differentiated based on morphological characteristics, yet with only moderate inter- and intraobserver agreement [4, 5]. A seven-marker immunohistochemical panel was demonstrated to discriminate grade 3 EEC from serous carcinoma with a 100% concordance rate in a series of 116 cases [4]. L1 cell adhesion molecule (L1CAM) has consistently shown to be a strong prognostic biomarker for identification of patients with poor outcome, and is more frequently expressed in NEECs. Although L1CAM is very good in identification of NEECs, only 14-40% of the grade 3 EECs express L1CAM [6-8]. Since grade 3 EECs have comparable aggressive tumour behaviour as NEECs, and both need more extensive surgery, the clinical need is mainly to improve identification of high grade EC [9-14]. Insulin-like growth factor-II mRNA-binding protein 3 (IMP3), also known as L523S or KOC (K-homologous domain-containing protein overexpressed in cancer) is an oncofoetal protein that
plays a role in tumour growth, migration and invasion [15]. It is a member of a family of RNA-binding proteins consisting of IMP1, IMP2 and IMP3 [16]. IMP3 is described as a diagnostic and prognostic biomarker in different types of cancer and as a possible therapeutic target [17-20]. In ECs, IMP3 was shown to be more frequently expressed in NEEC, mainly serous carcinomas [21-24]. Although the expression of IMP3 in NEECs might be clinically relevant, expression in EECs has been limited studied [21-25]. Our hypothesis was that IMP3 could contribute to the identification of high-grade EEC in addition to L1CAM, and therefore improve discrimination between low- and high-risk ECs. The aim of this study is to investigate the diagnostic and prognostic value of IMP3 in the discrimination between low- and high-grade ECs, and its added value to L1CAM.

2. Materials and Methods

2.1. Patients

Out of 1199 patients from a previously described ENITEC collaboration study cohort, 400 were randomly selected [6]. The randomly selected patients were not statistically different from the original cases for all variables shown in Table 1. Of these 400 selected patients, 19 patients were excluded because no more blank slides were available, and three patients were excluded after immunohistochemical staining due to lack of EC tissue. In total, 378 patients were included in the present study. The cohort consists of patients treated for an EC at one of the collaborating European Network for Individualised Treatment of Endometrial Cancer (ENITEC) centres. Only patients with tumours diagnosed by a dedicated gynaecological pathologist, with complete data on treatment and pathology, including follow-up data of at least 36 months were selected. Clinical and pathological data were recorded from the patient files into a database.
2.2. Tissue and staining

Blank 4µm thick sections were cut from formalin-fixed, paraffin-embedded tissue blocks and were sent to the Radboud university medical centre. After antigen retrieval, achieved with the Thermo Scientific PT Module in EDTA pH 9 for 10 minutes, and endogenous peroxidase blocking, slides were incubated with IMP3 antibody (Clone 69.1, Dako, Glostrup, Denmark, dilution 1:50). They were subsequently incubated with PowerVision+ Poly-HRP and visualized with PowerVision DAB substrate solution (Leica Biosystems, Buffalo Grove, IL, US). Finally, the slides were counterstained with haematoxylin, dehydrated, and mounted. L1CAM staining was performed as described previously [6].

2.3. Scoring

Slides stained for IMP3 were scored semiquantitatively. The final score was the product of the staining intensity and staining area scores of the cytoplasmic staining. Staining intensity was graded from 0 (no staining) to 3 (strong staining) (Figure 1). The area was scored as 0 (no tumour cells positive), 1 (<10% of the tumour cells positive), 2 (10-50% of the tumour cells positive), and 3 (>50% of the tumour cells positive). Scoring was independently performed by two investigators (NCMV and AE). In case of disagreement the case was discussed, and a consensus score was determined. For IMP3, a staining index of ≥4 was considered as positive [25]. L1CAM membranous expression was scored as previously described, and L1CAM was considered to be positive in case of >10% stained tumour cells [6].

2.4. Statistical analysis

Clinicopathological differences between IMP3 negative and positive tumours were calculated with Chi-square and Fisher’s exact tests for categorical, and the Mann-Whitney U test for continuous variables. Interobserver variability for IMP3 score was calculated using Cohen’s Kappa.
To investigate the diagnostic value of IMP3 and its added value to L1CAM, a receiver-operator characteristic (ROC) curve was constructed for the discrimination between low- and high-grade ECs based on IMP3 and L1CAM expression. Low-grade ECs were defined as histological grade 1 or grade 2 differentiated endometrioid carcinomas, and high-grade ECs were defined as histological grade 3 differentiated endometrioid carcinomas and all non-endometrioid carcinomas. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and the area under the receiver-operator characteristic curve (ROC AUC) were calculated. Binary logistic regression was used to calculate Odds Ratios (OR) and 95% Confidence Interval (CI) for discrimination between low- and high-grade ECs. Subsequently, we performed the same analyses within the subgroup of patients with endometrioid ECs and for the discrimination between endometrioid and non-endometrioid carcinomas.

To analyze the prognostic value, hazard ratios (HR) and 95% CI for 5-year overall and recurrence-free survival in relation to IMP3 and L1CAM expression were calculated using Cox regression analysis.

A p-value of <0.05 was considered to be significant for statistical differences. SPSS version 21 (SPSS IBM, New York, USA) statistical software was used to perform the statistical analyses.

2.5. Ethical approval

The study was approved by the institutional review board (IRB) of all participating centres.

3. Results

Clinicopathological characteristics of the 378 included patients are shown in Table 1, as well as characteristics of patients separated according to IMP3 and L1CAM expression. Of the 378...
included patients, 346 had an EEC and 32 a NEEC. Of the patients with a NEEC the primary non-endometrioid component was serous in 19 patients, clear cell in 8, carcinosarcoma in 4 and undifferentiated in 1 patient.

3.1. Expression of IMP3 and L1CAM

There was a substantial agreement in IMP3 scoring between the two observers (kappa=0.78). IMP3 was expressed in 24.6% (n=93) of the tumours. IMP3 expression was significantly associated with advanced stage, non-endometrioid type, grade 3 tumours, deep myometrial invasion, lymphovascular space invasion (LVSI), distant recurrences, overall mortality, and disease-related mortality (Table 1).

IMP3 expression was observed in 15% of the grade 1 and 2 EECs, 46% of the grade 3 EECs and in 84% of the NEECs (Table 2). Within the different subgroups of NEECs 84% of the serous carcinomas, 75% of clear cell carcinomas and all carcinosarcomas and undifferentiated carcinomas were positive for IMP3. L1CAM expression was present in 8% of the grade 1 and 2 EECs, 32% of the grade 3 EECs and in 78% of the NEECs.

The majority of the IMP3 negative tumours was also negative for L1CAM (93%) (Table 2). Of the IMP3 positive tumours 45% showed L1CAM expression, whereas 55% were L1CAM negative. These IMP3 positive, L1CAM negative tumours were mainly endometrioid tumours (88%) with low stage (88%) and low-grade (71%). Examples of positive and negative tumours are illustrated in Figure 2. In general, IMP3 showed a more homogeneous expression pattern compared to L1CAM, which more often showed a patchy expression (Figure 2 J-L).

3.2. Diagnostic value

High-grade ECs more frequently express IMP3 (63%) than L1CAM (52%). Absence of both IMP3 and L1CAM expression was associated with low-grade EC (OR 11.0; 95% CI 6.1-
19.9), and showed the highest AUC for discriminating between low- and high-grade ECs (AUC 0.766) (Table 3). In case a tumour was negative for both IMP3 and L1CAM there was a 93% chance the EC was low-grade. A combination with one positive marker and one negative marker had less diagnostic value, both within a combination of EECs and NEECs, and within the subgroup of EECs (Table 3). A combination of both IMP3 and L1CAM expression was strongly associated with high-grade EEC and NEEC (OR 19.7; 95% CI 9.2-42.2). Results for the different combinations of IMP3 and L1CAM within the subgroup of EECs were comparable. Within the subgroup EECs, combined IMP3 and L1CAM expression was strongly associated with high-grade EC (OR 8.6; 95% CI 3.4-21.9).

For differentiating between EECs and NEECs, both a combination of IMP3 and L1CAM, and use of IMP3 and L1CAM individually were accurate markers (Table S1). A combination of negative IMP3 and negative L1CAM expression showed both a very high positive predictive value for diagnosing EEC (100%) and a high negative predictive value (72%), and was better than L1CAM alone (Table S1). Results for discrimination between EECs and NEECs within high-grade EC were comparable.

3.3. Prognostic value

Overall, patients with tumours expressing IMP3 showed a reduced 5-year overall survival (HR 2.0; 95% CI 1.1-3.8), without a significant difference in recurrence-free survival (HR 1.9; 95% CI 0.97-3.6). Tumours expressing L1CAM showed both a reduced overall survival (HR 4.7; 9% CI 2.5-8.7) and recurrence-free survival (HR 2.8; 95% CI 1.4-5.6).

However, within the subgroup of patients with stage I EECs neither IMP3 (HR 1.2; 95% CI 0.5-3.4), nor L1CAM (HR 1.4; 95% CI 0.4-4.9) showed a significant difference in recurrence-free, and overall survival (HR 1.1; 95% CI 0.3-3.9 and HR 2.4; 95% CI 0.7-8.4, respectively). In addition, within the subgroup of patients with low-grade EECs, neither IMP3 (HR 0.9;
95% CI 0.3-3.1), nor L1CAM (HR 0.6; 95% CI 0.1-4.6) showed a significant difference in recurrence-free, and overall survival (HR 0.8; 95% CI 0.2-3.5 and HR 1.8; 95% CI 0.4-7.7, respectively).

4. Discussion

In this large multicenter study we showed that IMP3 has additional value as diagnostic biomarker in ECs. Combination of IMP3 and L1CAM expression was demonstrated to be superior to IMP3 and L1CAM alone for the discrimination between low- and high-grade ECs. IMP3 is a novel marker that was reported to be more frequently expressed in serous compared to EECs [21-24]. In three studies that evaluated 118, 122 and 311 EECs, respectively, IMP3 expression was more often found in high-grade EECs compared (20-39%) to low-grade EECs (3-9%), which is in line with the results of our study were we found expression in 46% and 15% of the high- and low-grade EECs respectively [21, 22, 25]. Both Mhawech-Fauceglia et al. (2013) and Li et al. used a combination of intensity and percentage of positive cells [22, 25]. However, one study did not find a relation between IMP3 expression and grade in EECs [24]. This conflicting result might be explained by the limited amount of patients with EEC in the latter study (n=57) and the different scoring system used (≥5% staining scored as positive) [24].

During the last years more and more diagnostic and prognostic markers, such as oestrogen receptor (ER), progesterone receptor (PR) and p53 have been studied in ECs [26]. Recently, L1CAM has established its role as a prognostic biomarker in ECs [6, 27-29]. Dellinger et al. have studied L1CAM gene expression in het The Cancer Genome Atlas (TCGA) RNA-seq dataset and have shown that L1CAM gene expression is an independent predictor of poor survival in EC patients [30]. IMP3 is a relatively new marker, and it has not been extensively studied in EECs. Although the pathophysiological mechanisms of L1CAM and IMP3 are
quite different, both show increased expression in NEECs and are associated with aggressive tumour characteristics [6, 15, 16, 27-29, 31]. Previous studies have analyzed the relationship between L1CAM, p53, ER and PR, but focussed on prognostic rather than diagnostic capacity [7, 32]. To our knowledge, this is the first study investigating the added value of IMP3 to L1CAM as diagnostic biomarker. We have shown that combining these two biomarkers significantly improves the discrimination between low- and high-grade ECs in the present study cohort compared to both markers individually.

NEECs and high-grade EECs require more extensive surgical treatment than low-grade EECs, which means that distinguishing low- and high-grade ECs is highly clinically relevant. Discrimination between low- and high grade ECs based on morphology alone, can be challenging for pathologists with only a moderate interobserver agreement in EECs [33-35]. Addition of immunohistochemical stainings might improve this agreement. Since L1CAM is expressed in only 14-40% of the grade 3 EECs, this is a limitation in its use for identification of all patients with high-grade carcinomas [6-8]. Even with some overlap in IMP3 and L1CAM expression, we found more IMP3 expression in both grade 3 EECs and NEECs compared to L1CAM. The present study has shown that the combination of IMP3 and L1CAM expression is most optimal to discriminate between low- and high-grade ECs. IMP3 negative, L1CAM negative tumours were 11 times more likely to be low-grade than ECs expressing one or both of these markers. These findings remained the same when NEECs were excluded. The high positive predictive value of this combination might be useful in selecting patients that do not require extensive surgery or adjuvant therapy.

While a combination of IMP3 and L1CAM is optimal to discriminate between low- and high grade ECs, this combination showed comparable results with L1CAM for discrimination between EECs and NEECs. However, since patients with high-grade EECs NEECs have
comparable outcome, discrimination between low- and high-grade ECs is more clinically relevant than the discrimination between EECs and NEECs [9-12].

Current results are based on the hysterectomy specimen, whereas the surgical treatment is determined on the preoperative histological diagnosis. Overall, there is only 67% agreement concerning tumour grade between preoperative endometrial sampling and final diagnosis [36]. Addition of immunohistochemistry might help differentiating between low- and high-risk patients preoperatively. The immunohistochemical stains in the current study were performed on whole slide, whereas most previous studies on the prognostic value of IMP3 have used tissue microarray (TMA) [21, 23, 25]. Based on preliminary data of own research, IMP3 showed a more homogeneous expression than L1CAM. The more homogeneous expression might be important in case of staining on preoperative biopsies. Therefore, IMP3 might be valuable in identification of high-risk patients on preoperative histology.

The strength of this study is the large number of included patients of different grades and types, and the median follow-up of 61 months (range 1-205 months). This long follow-up minimized the chance of missing recurrences and deaths.

A limitation of this study is the retrospective design which could cause a selection bias. We did not find additional prognostic value of IMP3. In contrast to the previous study, we did not find a prognostic value of L1CAM in patients with stage I EECs in this randomly selected cohort of 400 patients out of 1199 from the original study cohort [6]. Therefore, the lack of prognostic value of IMP3 in this study might be because of selection bias or the limited number of patients.

The histology was not revised centrally. However, all participating pathologists were dedicated gynaecological pathologists. Whether this is a limitation or strength could be debated. By using the local histological diagnoses, the results of this study are applicable to daily practice in hospitals which employ dedicated pathologists.
5. Conclusions
In conclusion, IMP3 has good diagnostic value and together with L1CAM represent the optimal combination of diagnostic markers for discrimination between low- and high-grade ECs compared to IMP3 and L1CAM alone, regardless of histological type. Because of the homogenous expression of IMP3, this marker might be valuable in preoperative biopsies when compared to the more patchy L1CAM expression.

6. Acknowledgements
The authors thank Monique Link and Kiek Verrijp for excellent technical assistance. FA is senior investigator for the Research Fund Flanders (F.W.O.).

References
[3] Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983; 15, 10-7,


[33] Lax SF, Kurman RJ, Pizer ES, Wu L, Ronnett BM. A binary architectural grading system for uterine endometrial endometrioid carcinoma has superior reproducibility compared with FIGO grading and identifies subsets of advance-stage tumors with favorable and unfavorable prognosis. Am J Surg Pathol 2000; 24, 1201-8,


Figures

Figure 1

IMP3 staining intensities. A, negative; B, weak; C, moderate; D, strong.
Figure 2

**IMP3 and L1CAM expression, representative cases.** A-C, Grade 1 endometrioid endometrial carcinoma (EEC) with negative IMP3 (B) and L1CAM (C) staining; D-F, Grade 3 EEC with positive IMP3 (E) and negative L1CAM (F) staining; G-I, Mixed carcinoma with EEC component negative for both IMP3 and L1CAM (H and I) and clear cell component positive for both IMP3 and L1CAM (H and I); J-L, Serous carcinoma (SC) with homogeneous expression of IMP3 (K) and patchy expression of L1CAM (L).
## Table 1. Clinicopathological characteristics

<table>
<thead>
<tr>
<th></th>
<th>All</th>
<th>IMP3-</th>
<th>IMP3+</th>
<th>(P^a)</th>
<th>L1CAM-</th>
<th>L1CAM+</th>
<th>(P^a)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Number of patients</strong></td>
<td>378</td>
<td>285 (75%)</td>
<td>93 (25%)</td>
<td></td>
<td>317 (84%)</td>
<td>61 (16%)</td>
<td></td>
</tr>
<tr>
<td><strong>Median age (years)</strong></td>
<td>63 (range 31-88)</td>
<td>63 (range 31-87)</td>
<td>64 (range 37-88)</td>
<td>0.109</td>
<td>62 (range 31-87)</td>
<td>69 (range 43-88)</td>
<td>&lt;0.001(^c)</td>
</tr>
<tr>
<td><strong>Median follow-up(^b) (months)</strong></td>
<td>61 (range 1-205)</td>
<td>62 (range 1-194)</td>
<td>57 (range 6-205)</td>
<td>0.221</td>
<td>62 (range 1-205)</td>
<td>54 (range 4-185)</td>
<td>0.020(^c)</td>
</tr>
<tr>
<td><strong>Treatment</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lymphadenectomy</td>
<td>236</td>
<td>177 (62%)</td>
<td>59 (63%)</td>
<td>0.902</td>
<td>189 (60%)</td>
<td>47 (77%)</td>
<td>0.010(^c)</td>
</tr>
<tr>
<td>Positive nodes</td>
<td>20</td>
<td>11 (6%)</td>
<td>9 (15%)</td>
<td>0.054</td>
<td>12 (6%)</td>
<td>8 (17%)</td>
<td>0.035(^c)</td>
</tr>
<tr>
<td>Radiotherapy</td>
<td>167</td>
<td>120 (42%)</td>
<td>47 (51%)</td>
<td>0.186</td>
<td>136 (43%)</td>
<td>31 (51%)</td>
<td>0.318</td>
</tr>
<tr>
<td>Chemotherapy</td>
<td>32</td>
<td>16 (6%)</td>
<td>16 (17%)</td>
<td>0.001(^c)</td>
<td>21 (7%)</td>
<td>11 (18%)</td>
<td>0.007(^c)</td>
</tr>
<tr>
<td><strong>FIGO 2009 stage</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stage I</td>
<td>319</td>
<td>252 (88%)</td>
<td>67 (72%)</td>
<td>&lt;0.001(^c)</td>
<td>283 (89%)</td>
<td>36 (59%)</td>
<td>&lt;0.001(^c)</td>
</tr>
<tr>
<td>Stage II-IV</td>
<td>59</td>
<td>33 (12%)</td>
<td>26 (28%)</td>
<td></td>
<td>34 (11%)</td>
<td>25 (41%)</td>
<td></td>
</tr>
<tr>
<td><strong>Histology</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endometrioid</td>
<td>346</td>
<td>280 (98%)</td>
<td>66 (71%)</td>
<td>&lt;0.001(^c)</td>
<td>310 (98%)</td>
<td>36 (59%)</td>
<td>&lt;0.001(^c)</td>
</tr>
<tr>
<td>Non-endometrioid</td>
<td>32</td>
<td>5 (2%)</td>
<td>27 (29%)</td>
<td></td>
<td>7 (2%)</td>
<td>25 (41%)</td>
<td></td>
</tr>
<tr>
<td><strong>Grade (only EEC)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 or 2</td>
<td>305</td>
<td>258 (92%)</td>
<td>47 (71%)</td>
<td>&lt;0.001(^c)</td>
<td>282 (91%)</td>
<td>23 (64%)</td>
<td>&lt;0.001(^c)</td>
</tr>
<tr>
<td>3</td>
<td>41</td>
<td>22 (8%)</td>
<td>19 (29%)</td>
<td></td>
<td>28 (9%)</td>
<td>13 (36%)</td>
<td></td>
</tr>
<tr>
<td><strong>Myometrial invasion</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;1/2</td>
<td>248</td>
<td>198 (69%)</td>
<td>50 (54%)</td>
<td>0.008(^c)</td>
<td>219 (69%)</td>
<td>29 (48%)</td>
<td>0.001(^c)</td>
</tr>
<tr>
<td>(\geq 1/2)</td>
<td>130</td>
<td>87 (31%)</td>
<td>43 (46%)</td>
<td></td>
<td>98 (31%)</td>
<td>32 (53%)</td>
<td></td>
</tr>
<tr>
<td><strong>LVSI</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>214</td>
<td>168 (59%)</td>
<td>46 (49%)</td>
<td>&lt;0.001(^c)</td>
<td>193 (61%)</td>
<td>21 (34%)</td>
<td>&lt;0.001(^c)</td>
</tr>
<tr>
<td>Yes</td>
<td>53</td>
<td>27 (10%)</td>
<td>26 (28%)</td>
<td></td>
<td>32 (10%)</td>
<td>21 (34%)</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>111</td>
<td>90 (32%)</td>
<td>21 (23%)</td>
<td></td>
<td>92 (29%)</td>
<td>19 (31%)</td>
<td></td>
</tr>
<tr>
<td><strong>Outcome</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Residual disease</td>
<td>11</td>
<td>6 (2%)</td>
<td>5 (5%)</td>
<td>0.148</td>
<td>4 (1%)</td>
<td>7 (12%)</td>
<td>&lt;0.001(^c)</td>
</tr>
<tr>
<td>Recurrence</td>
<td>43</td>
<td>28 (10%)</td>
<td>15 (17%)</td>
<td>0.087</td>
<td>30 (10%)</td>
<td>13 (24%)</td>
<td>0.002(^c)</td>
</tr>
<tr>
<td>Locoregional</td>
<td>23</td>
<td>19 (7%)</td>
<td>4 (5%)</td>
<td>0.615</td>
<td>20 (6%)</td>
<td>3 (6%)</td>
<td>0.815</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------------------</td>
<td>-----</td>
<td>----------</td>
<td>------</td>
<td>-------</td>
<td>-------</td>
<td>---------</td>
<td>-------</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Distant</td>
<td>29</td>
<td>16 (6%)</td>
<td>13</td>
<td>(15%)</td>
<td>0.011c</td>
<td>18 (6%)</td>
<td>11</td>
</tr>
<tr>
<td>Deceased</td>
<td>51</td>
<td>32 (11%)</td>
<td>19</td>
<td>(20%)</td>
<td>0.035c</td>
<td>32 (10%)</td>
<td>19</td>
</tr>
<tr>
<td>Endometrial cancer</td>
<td>30</td>
<td>15 (5%)</td>
<td>15</td>
<td>(16%)</td>
<td>0.002c</td>
<td>16 (5%)</td>
<td>14</td>
</tr>
</tbody>
</table>

*a*P-value for Chi-square-test for categorical variables. For nominal variables Mann-Whitney U test was performed; *b*Median follow-up including deceased patients; *c*Statistically significant.

Abbreviations: IMP3, Insulin-like growth factor-II mRNA-binding protein 3; FIGO, International Federation of Gynaecology and Obstetrics; EEC, endometrioid endometrial carcinoma; LVSI, lymphovascular space invasion.
Table 2. IMP3 and L1CAM expression in different subgroups.

<table>
<thead>
<tr>
<th>IHC marker</th>
<th>EEC grade 1-2</th>
<th>EEC grade 3</th>
<th>NEEC</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>IMP3+/L1CAM+</td>
<td>11 (26%)</td>
<td>10 (24%)</td>
<td>21 (50%)</td>
<td>42</td>
</tr>
<tr>
<td>IMP3+/L1CAM-</td>
<td>36 (71%)</td>
<td>9 (18%)</td>
<td>6 (12%)</td>
<td>51</td>
</tr>
<tr>
<td>IMP3-/L1CAM+</td>
<td>12 (63%)</td>
<td>3 (16%)</td>
<td>4 (21%)</td>
<td>19</td>
</tr>
<tr>
<td>IMP3-/L1CAM-</td>
<td>246 (93%)</td>
<td>19 (7%)</td>
<td>1 (0.4%)</td>
<td>266</td>
</tr>
</tbody>
</table>

Abbreviations: NEEC, non-endometrioid endometrial carcinoma; EEC, endometrioid endometrial carcinoma
Table 3. Logistic regression analysis of the prediction of low- and high-grade endometrial carcinoma in all included patients.

<table>
<thead>
<tr>
<th>IHC marker</th>
<th>OR</th>
<th>95% CI</th>
<th>Sensitivity</th>
<th>Specificity</th>
<th>PPV</th>
<th>NPV</th>
<th>ROC AUC</th>
<th>Positive level</th>
</tr>
</thead>
<tbody>
<tr>
<td>IMP3+</td>
<td>9.4^[a]</td>
<td>5.3-16.5</td>
<td>63%</td>
<td>85%</td>
<td>50%</td>
<td>91%</td>
<td>0.738</td>
<td>Grade 3</td>
</tr>
<tr>
<td>L1CAM+</td>
<td>13.3^[a]</td>
<td>7.1-24.9</td>
<td>52%</td>
<td>93%</td>
<td>62%</td>
<td>89%</td>
<td>0.723</td>
<td>Grade 3</td>
</tr>
<tr>
<td>IMP3+/L1CAM+</td>
<td>19.7^[a]</td>
<td>9.2-42.2</td>
<td>43%</td>
<td>96%</td>
<td>74%</td>
<td>88%</td>
<td>0.694</td>
<td>Grade 3</td>
</tr>
<tr>
<td>IMP3+/L1CAM-</td>
<td>1.9</td>
<td>0.99-3.8</td>
<td>21%</td>
<td>88%</td>
<td>29%</td>
<td>82%</td>
<td>0.544</td>
<td>Grade 3</td>
</tr>
<tr>
<td>IMP3-/L1CAM+</td>
<td>2.6</td>
<td>0.98-6.8</td>
<td>10%</td>
<td>96%</td>
<td>37%</td>
<td>82%</td>
<td>0.528</td>
<td>Grade 3</td>
</tr>
<tr>
<td>IMP3-/L1CAM-</td>
<td>11.0^[a]</td>
<td>6.1-19.9</td>
<td>81%</td>
<td>73%</td>
<td>93%</td>
<td>47%</td>
<td>0.766</td>
<td>Grade 1-2</td>
</tr>
</tbody>
</table>

^[a]Statistically significant.

Abbreviations: OR, Odds Ratio; CI, Confidence Interval; PPV, Positive predictive value; NPV, Negative predictive value; ROC AUC, area under the receiver-operator characteristic curve
Table S1. Logistic regression analysis of the prediction of endometrioid and non-endometrioid carcinoma in all included patients.

<table>
<thead>
<tr>
<th>IHC marker</th>
<th>OR</th>
<th>95% CI</th>
<th>Sensitivity</th>
<th>Specificity</th>
<th>PPV</th>
<th>NPV</th>
<th>ROC AUC</th>
<th>Positive level</th>
</tr>
</thead>
<tbody>
<tr>
<td>IMP3+</td>
<td>22.9(^a)</td>
<td>8.5-61.7</td>
<td>84%</td>
<td>81%</td>
<td>29%</td>
<td>98%</td>
<td>0.826</td>
<td>NEEC</td>
</tr>
<tr>
<td>L1CAM+</td>
<td>30.8(^a)</td>
<td>12.4-76.1</td>
<td>78%</td>
<td>90%</td>
<td>41%</td>
<td>98%</td>
<td>0.839</td>
<td>NEEC</td>
</tr>
<tr>
<td>IMP3+/L1CAM+</td>
<td>29.5(^a)</td>
<td>12.6-69.3</td>
<td>66%</td>
<td>94%</td>
<td>50%</td>
<td>97%</td>
<td>0.798</td>
<td>NEEC</td>
</tr>
<tr>
<td>IMP3+/L1CAM-</td>
<td>1.5</td>
<td>0.6-4.0</td>
<td>19%</td>
<td>87%</td>
<td>12%</td>
<td>92%</td>
<td>0.529</td>
<td>NEEC</td>
</tr>
<tr>
<td>IMP3-/L1CAM+</td>
<td>3.2</td>
<td>0.98-10.1</td>
<td>13%</td>
<td>96%</td>
<td>21%</td>
<td>92%</td>
<td>0.541</td>
<td>NEEC</td>
</tr>
<tr>
<td>IMP3-/L1CAM-</td>
<td>101.4(^a)</td>
<td>13.6-754.5</td>
<td>77%</td>
<td>97%</td>
<td>100%</td>
<td>28%</td>
<td>0.867</td>
<td>EEC</td>
</tr>
</tbody>
</table>

\(^a\)Statistically significant.

Abbreviations: OR, Odds Ratio; CI, Confidence Interval; PPV, Positive predictive value; NPV, Negative predictive value; ROC AUC, area under the receiver-operator characteristic curve; NEEC, non-endometrioid endometrial carcinoma; EEC, endometrioid endometrial carcinoma